LivaNova Reports $357.8 Million Revenue in Q3 2025, Net Loss of $273.4 Million for Nine Months

LivaNova PLC reported a net revenue of $357.8 million for the third quarter of 2025, marking a 12.4% increase from $318.1 million in the same period of 2024. For the nine months ending September 30, 2025, the company achieved revenues of $1.03 billion, up 10.3% from $931.6 million year-over-year. The gross profit for the quarter was $244.9 million, compared to $221.0 million in the prior year, while the operating income rose to $54.0 million from $35.6 million. However, the company reported a net loss of $273.4 million for the nine months, a significant decline from a net income of $7.3 million in the same period last year, primarily due to a substantial environmental liability expense related to the SNIA litigation.

The company’s financial performance reflects notable changes compared to the previous fiscal period, particularly in operating income, which increased significantly due to higher revenues and reduced litigation provisions. The Cardiopulmonary segment saw a revenue increase of 18.0% in Q3 2025, driven by strong demand for the Essenz Perfusion System and consumables. The Neuromodulation segment also contributed to growth, with a 6.9% increase in revenue for the same quarter, supported by the VNS Therapy System for drug-resistant epilepsy.

Strategically, LivaNova has focused on enhancing its core segments through the 2024 Restructuring Plan, which aims to streamline operations and improve profitability. The company has also been active in managing its debt, having made an early repayment of $200 million on principal borrowings under its Term Facilities in May 2025, which resulted in a loss on debt extinguishment of $2.7 million. Additionally, LivaNova has been involved in ongoing clinical studies, including the CORE-VNS study for epilepsy and the OSPREY trial for obstructive sleep apnea, which are expected to bolster its product offerings.

Operationally, LivaNova reported a total employee headcount of approximately 2,500 as of September 30, 2025, reflecting a stable workforce amid ongoing strategic initiatives. The company continues to expand its geographic footprint, with significant revenue contributions from the U.S., Europe, and the Rest of World regions. The U.S. market accounted for $190.4 million in Q3 2025, while Europe and the Rest of World contributed $67.7 million and $99.6 million, respectively.

Looking ahead, LivaNova anticipates continued revenue growth driven by its innovative product offerings and strategic focus on core segments. However, the company remains cautious about potential challenges, including macroeconomic factors such as inflation and supply chain disruptions, which could impact future performance. The management has expressed confidence in its liquidity position, supported by cash and cash equivalents of $646.1 million as of September 30, 2025, and believes it has sufficient resources to meet operational needs and obligations in the coming year.